Newborn Screening Translational Research Network (NBSTRN)
Please visit NBSTRN at Booth 538
Every day, babies born in the United States receive comprehensive screening for treatable diseases. Newborn screening saves lives, and discoveries by researchers make it possible! ACMG operates the Newborn Screening Translational Research Network (NBSTRN) with the goal of accelerating discoveries in newborn screening. Founded in 2008 as a key component of the Hunter Kelly Newborn Screening Program at the Eunice Kennedy Shriver National Institutes of Child Health and Human Development (NICHD) through a contract with the American College of Medical Genetics and Genomics (ACMG), NBSTRN has grown into an international network involved in supporting cutting edge research, population-based pilots and ethical, legal, and social (ELSI) discussions. NBSTRN's vision is to facilitate and support ground-breaking research to accelerate understanding of genetic disease, with the goal of increasing the number of screened conditions and fostering collaborations with clinicians, families, and health professionals to understand and maximize health outcomes. NBSTRN is a key component of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Hunter Kelly Newborn Screening Research Program. This project is funded in whole or in part with Federal funds from the NICHD, National Institute of Health, Department of Health and Human Services, under Contract No. HHSN275201800005C. Please visit https://www.nbstrn.org for more information.